In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA<sub>2</sub>DS<sub>2</sub>-VASc >4.
Where this comes from
- Record sourced from PubMed, PMID 39496171.
- Also identified by DOI 10.7326/ANNALS-24-02625-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lopes RD, Granger CB, Wojdyla DM, et al. <b>Apixaban vs aspirin according to CHA<sub>2</sub>DS<sub>2</sub>-VASc score in subclinical atrial fibrillation: insights from ARTESiA.</b> J Am Coll Cardiol. 2024;84:354-364. 39019530.
Medical subject headings
- Pyridones
- Aspirin
- Atrial Fibrillation
- Pyrazoles
- Stroke
- Factor Xa Inhibitors